Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies ...

Additionally, one other acromegaly abstract – a real-world evidence ... Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board ...

Q1 2025 Earnings Call Transcript May 8, 2025 Crinetics Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.04 EPS, expectations were $-0.99. Operator: And the call will begin ...

Crinetics Pharmaceuticals, Inc.’s CRNX share price has surged by 8.07%, which has investors questioning if this is right time to sell.

We are on-track with the FDA review and preparations for the anticipated launch of paltusotine for acromegaly, while also moving forward ... Graves’ disease (including thyroid eye disease), diabetes, ...

Acromegaly is characterized by excessive growth hormone (GH) and insulin-like growth factor 1 (IGF-1) and affects quality of life and mortality. Oczyesa was submitted in a hybrid application ...

1 "We are pleased with the CHMP's positive recommendation for market authorization for Oczyesa octreotide monthly depot for the treatment of acromegaly", says Fredrik Tiberg, President & CEO at ...

LUND, Sweden - Camurus (market cap: $55.97M) announced today that the Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for the market authorization of Oczyesa®, a ...